Clinical Takeaway
Trauma-focused therapy remains effective for PTSD even in patients who are actively using cannabis, including those with co-occurring substance use disorders. Patients should not be required to stop cannabis use before beginning evidence-based PTSD treatment, as withholding trauma-focused care on that basis is not supported by this data.
#5 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis directly addresses a critical clinical gap by examining whether evidence-based trauma-focused treatments maintain efficacy in patients with comorbid PTSD and substance use disorders who also use cannabis, a population frequently excluded from or underrepresented in prior treatment trials. The findings clarify treatment selection and prognostication for a substantial proportion of PTSD+SUD patients in real-world clinical settings, where cannabis use is prevalent and often concurrent with other substance use. Understanding differential treatment response in cannabis-using versus non-using patients with comorbid PTSD+SUD is essential for optimizing therapeutic outcomes and identifying whether modified treatment approaches are necessary for this high-risk population.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 While this meta-analysis contributes valuable data on an understudied population, several important limitations warrant cautious interpretation. The analysis draws from only four of thirty-six available RCTs, potentially introducing selection bias, and the heterogeneity of cannabis use patterns (frequency, potency, mode of administration) across participants remains unspecified, making it difficult to establish dose-response relationships or identify which patients might be most affected. Cannabis use disorder itself was not clearly distinguished from occasional use, and unmeasured confounders such as self-medication severity, trauma type, or cannabis-related expectancy effects could substantially influence outcomes. From a clinical standpoint, while this work appropriately challenges assumptions that cannabis use automatically disqualifies patients from evidence-based trauma treatment, providers should continue individualizing PTSD care for cannabis-using patients by assessing cannabis use patterns, exploring motivations for use, and considering whether concurrent cannabis reduction might enhance treatment engagement and response to trauma-focused therapies.